nodes	percent_of_prediction	percent_of_DWPC	metapath
Medroxyprogesterone Acetate—Progesterone—uterine cancer	0.297	1	CrCtD
Medroxyprogesterone Acetate—AKR1C3—uterine cancer	0.113	0.524	CbGaD
Medroxyprogesterone Acetate—PGR—uterine cancer	0.0627	0.291	CbGaD
Medroxyprogesterone Acetate—ESR1—uterine cancer	0.0396	0.184	CbGaD
Medroxyprogesterone Acetate—PGR—Progesterone—uterine cancer	0.0345	0.194	CbGbCtD
Medroxyprogesterone Acetate—SHBG—Progesterone—uterine cancer	0.0331	0.186	CbGbCtD
Medroxyprogesterone Acetate—AR—Progesterone—uterine cancer	0.0277	0.156	CbGbCtD
Medroxyprogesterone Acetate—ESR1—Progesterone—uterine cancer	0.0239	0.135	CbGbCtD
Medroxyprogesterone Acetate—AKR1C3—Doxorubicin—uterine cancer	0.0234	0.132	CbGbCtD
Medroxyprogesterone Acetate—Eplerenone—Progesterone—uterine cancer	0.0201	0.0987	CrCrCtD
Medroxyprogesterone Acetate—Ethynodiol—Progesterone—uterine cancer	0.0189	0.0926	CrCrCtD
Medroxyprogesterone Acetate—NR3C1—Progesterone—uterine cancer	0.0176	0.0992	CbGbCtD
Medroxyprogesterone Acetate—Dydrogesterone—Progesterone—uterine cancer	0.016	0.0784	CrCrCtD
Medroxyprogesterone Acetate—Drospirenone—Progesterone—uterine cancer	0.016	0.0784	CrCrCtD
Medroxyprogesterone Acetate—Spironolactone—Progesterone—uterine cancer	0.0152	0.0747	CrCrCtD
Medroxyprogesterone Acetate—Potassium Canrenoate—Progesterone—uterine cancer	0.0152	0.0747	CrCrCtD
Medroxyprogesterone Acetate—Megestrol acetate—Progesterone—uterine cancer	0.0139	0.0684	CrCrCtD
Medroxyprogesterone Acetate—Medrysone—Progesterone—uterine cancer	0.0129	0.0631	CrCrCtD
Medroxyprogesterone Acetate—Hydrocortamate—Progesterone—uterine cancer	0.0112	0.0549	CrCrCtD
Medroxyprogesterone Acetate—Cortisone acetate—Progesterone—uterine cancer	0.0108	0.0532	CrCrCtD
Medroxyprogesterone Acetate—Fluoxymesterone—Progesterone—uterine cancer	0.00966	0.0474	CrCrCtD
Medroxyprogesterone Acetate—Fludrocortisone—Progesterone—uterine cancer	0.00941	0.0462	CrCrCtD
Medroxyprogesterone Acetate—Testosterone Propionate—Progesterone—uterine cancer	0.00941	0.0462	CrCrCtD
Medroxyprogesterone Acetate—Methyltestosterone—Progesterone—uterine cancer	0.00918	0.0451	CrCrCtD
Medroxyprogesterone Acetate—Testosterone—Progesterone—uterine cancer	0.00817	0.0401	CrCrCtD
Medroxyprogesterone Acetate—Hydrocortisone—Progesterone—uterine cancer	0.00768	0.0377	CrCrCtD
Medroxyprogesterone Acetate—CYP2C8—Progesterone—uterine cancer	0.00606	0.0341	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Progesterone—uterine cancer	0.00423	0.0238	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Etoposide—uterine cancer	0.00271	0.0153	CbGbCtD
Medroxyprogesterone Acetate—PGR—corpus luteum—uterine cancer	0.0027	0.123	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Progesterone—uterine cancer	0.00246	0.0138	CbGbCtD
Medroxyprogesterone Acetate—SHBG—semen—uterine cancer	0.0014	0.0639	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Etoposide—uterine cancer	0.0011	0.0062	CbGbCtD
Medroxyprogesterone Acetate—AR—semen—uterine cancer	0.00101	0.0458	CbGeAlD
Medroxyprogesterone Acetate—PGR—oviduct—uterine cancer	0.000927	0.0422	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Doxorubicin—uterine cancer	0.00075	0.00423	CbGbCtD
Medroxyprogesterone Acetate—AKR1C3—Podofilox—Etoposide—uterine cancer	0.000744	1	CbGdCrCtD
Medroxyprogesterone Acetate—AR—oviduct—uterine cancer	0.000738	0.0336	CbGeAlD
Medroxyprogesterone Acetate—ESR1—oviduct—uterine cancer	0.000725	0.033	CbGeAlD
Medroxyprogesterone Acetate—PGR—artery—uterine cancer	0.000614	0.0279	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—female reproductive system—uterine cancer	0.000605	0.0276	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—female gonad—uterine cancer	0.00055	0.0251	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—myometrium—uterine cancer	0.000438	0.0199	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—lymph node—uterine cancer	0.000354	0.0161	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—uterine cervix—uterine cancer	0.000341	0.0155	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—smooth muscle tissue—uterine cancer	0.000331	0.0151	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—decidua—uterine cancer	0.000325	0.0148	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—endometrium—uterine cancer	0.000308	0.014	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—mammalian vulva—uterine cancer	0.000298	0.0136	CbGeAlD
Medroxyprogesterone Acetate—PGR—myometrium—uterine cancer	0.000296	0.0135	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—uterus—uterine cancer	0.000284	0.0129	CbGeAlD
Medroxyprogesterone Acetate—Dydrogesterone—PGR—uterine cancer	0.000244	0.169	CrCbGaD
Medroxyprogesterone Acetate—AR—myometrium—uterine cancer	0.000236	0.0108	CbGeAlD
Medroxyprogesterone Acetate—PGR—epithelium—uterine cancer	0.000233	0.0106	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—female gonad—uterine cancer	0.000232	0.0106	CbGeAlD
Medroxyprogesterone Acetate—ESR1—myometrium—uterine cancer	0.000232	0.0106	CbGeAlD
Medroxyprogesterone Acetate—SHBG—endometrium—uterine cancer	0.000232	0.0105	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—vagina—uterine cancer	0.000231	0.0105	CbGeAlD
Medroxyprogesterone Acetate—PGR—uterine cervix—uterine cancer	0.000231	0.0105	CbGeAlD
Medroxyprogesterone Acetate—PGR—smooth muscle tissue—uterine cancer	0.000224	0.0102	CbGeAlD
Medroxyprogesterone Acetate—PGR—decidua—uterine cancer	0.00022	0.01	CbGeAlD
Medroxyprogesterone Acetate—SHBG—uterus—uterine cancer	0.000213	0.00972	CbGeAlD
Medroxyprogesterone Acetate—Cyproterone acetate—CYP19A1—uterine cancer	0.000211	0.146	CrCbGaD
Medroxyprogesterone Acetate—PGR—endometrium—uterine cancer	0.000209	0.0095	CbGeAlD
Medroxyprogesterone Acetate—Ethynodiol—PGR—uterine cancer	0.000201	0.139	CrCbGaD
Medroxyprogesterone Acetate—PGR—uterus—uterine cancer	0.000192	0.00876	CbGeAlD
Medroxyprogesterone Acetate—SHBG—female reproductive system—uterine cancer	0.000192	0.00874	CbGeAlD
Medroxyprogesterone Acetate—AR—epithelium—uterine cancer	0.000185	0.00844	CbGeAlD
Medroxyprogesterone Acetate—AR—uterine cervix—uterine cancer	0.000184	0.00837	CbGeAlD
Medroxyprogesterone Acetate—ESR1—epithelium—uterine cancer	0.000182	0.00829	CbGeAlD
Medroxyprogesterone Acetate—ESR1—uterine cervix—uterine cancer	0.00018	0.00822	CbGeAlD
Medroxyprogesterone Acetate—AR—smooth muscle tissue—uterine cancer	0.000179	0.00814	CbGeAlD
Medroxyprogesterone Acetate—ESR1—smooth muscle tissue—uterine cancer	0.000175	0.00799	CbGeAlD
Medroxyprogesterone Acetate—AR—decidua—uterine cancer	0.000175	0.00798	CbGeAlD
Medroxyprogesterone Acetate—SHBG—female gonad—uterine cancer	0.000175	0.00795	CbGeAlD
Medroxyprogesterone Acetate—SHBG—vagina—uterine cancer	0.000174	0.0079	CbGeAlD
Medroxyprogesterone Acetate—PGR—female reproductive system—uterine cancer	0.000173	0.00787	CbGeAlD
Medroxyprogesterone Acetate—AR—renal system—uterine cancer	0.000172	0.00783	CbGeAlD
Medroxyprogesterone Acetate—ESR1—decidua—uterine cancer	0.000172	0.00783	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—myometrium—uterine cancer	0.000171	0.00779	CbGeAlD
Medroxyprogesterone Acetate—ESR1—renal system—uterine cancer	0.000169	0.00769	CbGeAlD
Medroxyprogesterone Acetate—AR—endometrium—uterine cancer	0.000166	0.00757	CbGeAlD
Medroxyprogesterone Acetate—ESR1—endometrium—uterine cancer	0.000163	0.00743	CbGeAlD
Medroxyprogesterone Acetate—AR—mammalian vulva—uterine cancer	0.000161	0.00732	CbGeAlD
Medroxyprogesterone Acetate—PGR—female gonad—uterine cancer	0.000157	0.00716	CbGeAlD
Medroxyprogesterone Acetate—PGR—vagina—uterine cancer	0.000156	0.00712	CbGeAlD
Medroxyprogesterone Acetate—AR—uterus—uterine cancer	0.000153	0.00698	CbGeAlD
Medroxyprogesterone Acetate—ESR1—uterus—uterine cancer	0.00015	0.00685	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—lymph node—uterine cancer	0.000149	0.0068	CbGeAlD
Medroxyprogesterone Acetate—Megestrol acetate—PGR—uterine cancer	0.000147	0.102	CrCbGaD
Medroxyprogesterone Acetate—CYP2C8—renal system—uterine cancer	0.000139	0.00633	CbGeAlD
Medroxyprogesterone Acetate—AR—female reproductive system—uterine cancer	0.000138	0.00627	CbGeAlD
Medroxyprogesterone Acetate—ESR1—female reproductive system—uterine cancer	0.000135	0.00616	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—endometrium—uterine cancer	0.000134	0.00612	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—epithelium—uterine cancer	0.000134	0.00612	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—uterine cervix—uterine cancer	0.000133	0.00606	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—smooth muscle tissue—uterine cancer	0.000129	0.00589	CbGeAlD
Medroxyprogesterone Acetate—Drospirenone—PGR—uterine cancer	0.000128	0.0889	CrCbGaD
Medroxyprogesterone Acetate—Ethynodiol—ESR1—uterine cancer	0.000127	0.088	CrCbGaD
Medroxyprogesterone Acetate—NR3C1—decidua—uterine cancer	0.000127	0.00578	CbGeAlD
Medroxyprogesterone Acetate—AR—female gonad—uterine cancer	0.000125	0.00571	CbGeAlD
Medroxyprogesterone Acetate—AR—vagina—uterine cancer	0.000125	0.00567	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—renal system—uterine cancer	0.000125	0.00567	CbGeAlD
Medroxyprogesterone Acetate—ESR1—female gonad—uterine cancer	0.000123	0.0056	CbGeAlD
Medroxyprogesterone Acetate—ESR1—vagina—uterine cancer	0.000122	0.00557	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—endometrium—uterine cancer	0.00012	0.00548	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—mammalian vulva—uterine cancer	0.000116	0.0053	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—female reproductive system—uterine cancer	0.000111	0.00507	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—uterus—uterine cancer	0.000111	0.00505	CbGeAlD
Medroxyprogesterone Acetate—PGR—lymph node—uterine cancer	0.000101	0.00461	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—vagina—uterine cancer	0.000101	0.00459	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—female reproductive system—uterine cancer	9.97e-05	0.00454	CbGeAlD
Medroxyprogesterone Acetate—CYP2C9—female reproductive system—uterine cancer	9.89e-05	0.00451	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—renal system—uterine cancer	9.42e-05	0.00429	CbGeAlD
Medroxyprogesterone Acetate—Spironolactone—PGR—uterine cancer	9.13e-05	0.0633	CrCbGaD
Medroxyprogesterone Acetate—NR3C1—female gonad—uterine cancer	9.08e-05	0.00413	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—vagina—uterine cancer	9.02e-05	0.00411	CbGeAlD
Medroxyprogesterone Acetate—AR—lymph node—uterine cancer	8.06e-05	0.00367	CbGeAlD
Medroxyprogesterone Acetate—ESR1—lymph node—uterine cancer	7.91e-05	0.0036	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—female reproductive system—uterine cancer	7.54e-05	0.00344	CbGeAlD
Medroxyprogesterone Acetate—Fluoxymesterone—ESR1—uterine cancer	6.3e-05	0.0436	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—CYP11A1—uterine cancer	6.2e-05	0.043	CrCbGaD
Medroxyprogesterone Acetate—NR3C1—lymph node—uterine cancer	5.83e-05	0.00266	CbGeAlD
Medroxyprogesterone Acetate—Methyltestosterone—CYP19A1—uterine cancer	5.52e-05	0.0383	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—PGR—uterine cancer	4.94e-05	0.0343	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—CYP19A1—uterine cancer	3.2e-05	0.0222	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—ESR1—uterine cancer	3.12e-05	0.0216	CrCbGaD
Medroxyprogesterone Acetate—Mood swings—Doxorubicin—uterine cancer	2.15e-05	0.000425	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Etoposide—uterine cancer	2.13e-05	0.000423	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal distension—Epirubicin—uterine cancer	2.13e-05	0.000422	CcSEcCtD
Medroxyprogesterone Acetate—Ataxia—Doxorubicin—uterine cancer	2.13e-05	0.000422	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Dactinomycin—uterine cancer	2.13e-05	0.000422	CcSEcCtD
Medroxyprogesterone Acetate—Blood creatinine increased—Doxorubicin—uterine cancer	2.12e-05	0.000421	CcSEcCtD
Medroxyprogesterone Acetate—Asthma—Epirubicin—uterine cancer	2.12e-05	0.000419	CcSEcCtD
Medroxyprogesterone Acetate—Influenza—Epirubicin—uterine cancer	2.12e-05	0.000419	CcSEcCtD
Medroxyprogesterone Acetate—Dysphagia—Epirubicin—uterine cancer	2.12e-05	0.000419	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Etoposide—uterine cancer	2.1e-05	0.000416	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Etoposide—uterine cancer	2.1e-05	0.000415	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Etoposide—uterine cancer	2.09e-05	0.000413	CcSEcCtD
Medroxyprogesterone Acetate—Dry skin—Doxorubicin—uterine cancer	2.08e-05	0.000411	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Etoposide—uterine cancer	2.08e-05	0.000411	CcSEcCtD
Medroxyprogesterone Acetate—Orthostatic hypotension—Doxorubicin—uterine cancer	2.07e-05	0.00041	CcSEcCtD
Medroxyprogesterone Acetate—Hypokalaemia—Doxorubicin—uterine cancer	2.06e-05	0.000409	CcSEcCtD
Medroxyprogesterone Acetate—Breast disorder—Doxorubicin—uterine cancer	2.05e-05	0.000406	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Etoposide—uterine cancer	2.05e-05	0.000405	CcSEcCtD
Medroxyprogesterone Acetate—Bronchitis—Epirubicin—uterine cancer	2.04e-05	0.000403	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Dactinomycin—uterine cancer	2.03e-05	0.000402	CcSEcCtD
Medroxyprogesterone Acetate—Nasopharyngitis—Doxorubicin—uterine cancer	2.03e-05	0.000401	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Etoposide—uterine cancer	2.01e-05	0.000397	CcSEcCtD
Medroxyprogesterone Acetate—Muscular weakness—Doxorubicin—uterine cancer	2e-05	0.000396	CcSEcCtD
Medroxyprogesterone Acetate—Alanine aminotransferase increased—Doxorubicin—uterine cancer	2e-05	0.000396	CcSEcCtD
Medroxyprogesterone Acetate—Dysuria—Epirubicin—uterine cancer	1.98e-05	0.000392	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal distension—Doxorubicin—uterine cancer	1.97e-05	0.000391	CcSEcCtD
Medroxyprogesterone Acetate—Upper respiratory tract infection—Epirubicin—uterine cancer	1.97e-05	0.00039	CcSEcCtD
Medroxyprogesterone Acetate—Dysphagia—Doxorubicin—uterine cancer	1.96e-05	0.000388	CcSEcCtD
Medroxyprogesterone Acetate—Influenza—Doxorubicin—uterine cancer	1.96e-05	0.000388	CcSEcCtD
Medroxyprogesterone Acetate—Asthma—Doxorubicin—uterine cancer	1.96e-05	0.000388	CcSEcCtD
Medroxyprogesterone Acetate—Pollakiuria—Epirubicin—uterine cancer	1.96e-05	0.000387	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Etoposide—uterine cancer	1.93e-05	0.000382	CcSEcCtD
Medroxyprogesterone Acetate—Weight increased—Epirubicin—uterine cancer	1.93e-05	0.000382	CcSEcCtD
Medroxyprogesterone Acetate—Weight decreased—Epirubicin—uterine cancer	1.92e-05	0.000379	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Etoposide—uterine cancer	1.92e-05	0.000379	CcSEcCtD
Medroxyprogesterone Acetate—Hyperglycaemia—Epirubicin—uterine cancer	1.91e-05	0.000378	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Etoposide—uterine cancer	1.91e-05	0.000378	CcSEcCtD
Medroxyprogesterone Acetate—Infestation—Epirubicin—uterine cancer	1.89e-05	0.000374	CcSEcCtD
Medroxyprogesterone Acetate—Drowsiness—Epirubicin—uterine cancer	1.89e-05	0.000374	CcSEcCtD
Medroxyprogesterone Acetate—Infestation NOS—Epirubicin—uterine cancer	1.89e-05	0.000374	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Dactinomycin—uterine cancer	1.89e-05	0.000374	CcSEcCtD
Medroxyprogesterone Acetate—Bronchitis—Doxorubicin—uterine cancer	1.88e-05	0.000373	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Dactinomycin—uterine cancer	1.87e-05	0.000371	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Etoposide—uterine cancer	1.87e-05	0.00037	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Etoposide—uterine cancer	1.86e-05	0.000367	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Etoposide—uterine cancer	1.85e-05	0.000367	CcSEcCtD
Medroxyprogesterone Acetate—Neuropathy peripheral—Epirubicin—uterine cancer	1.85e-05	0.000366	CcSEcCtD
Medroxyprogesterone Acetate—Stomatitis—Epirubicin—uterine cancer	1.84e-05	0.000364	CcSEcCtD
Medroxyprogesterone Acetate—Jaundice—Epirubicin—uterine cancer	1.84e-05	0.000364	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Etoposide—uterine cancer	1.84e-05	0.000364	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract infection—Epirubicin—uterine cancer	1.84e-05	0.000363	CcSEcCtD
Medroxyprogesterone Acetate—Dysuria—Doxorubicin—uterine cancer	1.83e-05	0.000363	CcSEcCtD
Medroxyprogesterone Acetate—Upper respiratory tract infection—Doxorubicin—uterine cancer	1.82e-05	0.000361	CcSEcCtD
Medroxyprogesterone Acetate—Sweating—Epirubicin—uterine cancer	1.81e-05	0.000358	CcSEcCtD
Medroxyprogesterone Acetate—Pollakiuria—Doxorubicin—uterine cancer	1.81e-05	0.000358	CcSEcCtD
Medroxyprogesterone Acetate—Hepatobiliary disease—Epirubicin—uterine cancer	1.79e-05	0.000354	CcSEcCtD
Medroxyprogesterone Acetate—Weight increased—Doxorubicin—uterine cancer	1.78e-05	0.000353	CcSEcCtD
Medroxyprogesterone Acetate—Epistaxis—Epirubicin—uterine cancer	1.78e-05	0.000353	CcSEcCtD
Medroxyprogesterone Acetate—Weight decreased—Doxorubicin—uterine cancer	1.77e-05	0.000351	CcSEcCtD
Medroxyprogesterone Acetate—Sinusitis—Epirubicin—uterine cancer	1.77e-05	0.000351	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Etoposide—uterine cancer	1.77e-05	0.000351	CcSEcCtD
Medroxyprogesterone Acetate—Hyperglycaemia—Doxorubicin—uterine cancer	1.77e-05	0.00035	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Dactinomycin—uterine cancer	1.76e-05	0.000349	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Etoposide—uterine cancer	1.76e-05	0.000348	CcSEcCtD
Medroxyprogesterone Acetate—Infestation NOS—Doxorubicin—uterine cancer	1.75e-05	0.000346	CcSEcCtD
Medroxyprogesterone Acetate—Infestation—Doxorubicin—uterine cancer	1.75e-05	0.000346	CcSEcCtD
Medroxyprogesterone Acetate—Drowsiness—Doxorubicin—uterine cancer	1.75e-05	0.000346	CcSEcCtD
Medroxyprogesterone Acetate—Bradycardia—Epirubicin—uterine cancer	1.73e-05	0.000342	CcSEcCtD
Medroxyprogesterone Acetate—Neuropathy peripheral—Doxorubicin—uterine cancer	1.71e-05	0.000339	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Etoposide—uterine cancer	1.71e-05	0.000338	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Epirubicin—uterine cancer	1.7e-05	0.000337	CcSEcCtD
Medroxyprogesterone Acetate—Stomatitis—Doxorubicin—uterine cancer	1.7e-05	0.000337	CcSEcCtD
Medroxyprogesterone Acetate—Jaundice—Doxorubicin—uterine cancer	1.7e-05	0.000337	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Etoposide—uterine cancer	1.7e-05	0.000336	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Etoposide—uterine cancer	1.7e-05	0.000336	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract infection—Doxorubicin—uterine cancer	1.7e-05	0.000336	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Epirubicin—uterine cancer	1.7e-05	0.000336	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Epirubicin—uterine cancer	1.7e-05	0.000336	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Epirubicin—uterine cancer	1.68e-05	0.000333	CcSEcCtD
Medroxyprogesterone Acetate—Sweating—Doxorubicin—uterine cancer	1.68e-05	0.000332	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Epirubicin—uterine cancer	1.67e-05	0.000331	CcSEcCtD
Medroxyprogesterone Acetate—Oedema peripheral—Epirubicin—uterine cancer	1.67e-05	0.000331	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Epirubicin—uterine cancer	1.67e-05	0.00033	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Epirubicin—uterine cancer	1.66e-05	0.000329	CcSEcCtD
Medroxyprogesterone Acetate—Hepatobiliary disease—Doxorubicin—uterine cancer	1.65e-05	0.000327	CcSEcCtD
Medroxyprogesterone Acetate—Epistaxis—Doxorubicin—uterine cancer	1.65e-05	0.000326	CcSEcCtD
Medroxyprogesterone Acetate—Sinusitis—Doxorubicin—uterine cancer	1.64e-05	0.000325	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Epirubicin—uterine cancer	1.63e-05	0.000323	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Epirubicin—uterine cancer	1.6e-05	0.000317	CcSEcCtD
Medroxyprogesterone Acetate—Bradycardia—Doxorubicin—uterine cancer	1.6e-05	0.000316	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Epirubicin—uterine cancer	1.58e-05	0.000314	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Etoposide—uterine cancer	1.58e-05	0.000313	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Epirubicin—uterine cancer	1.58e-05	0.000313	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Doxorubicin—uterine cancer	1.58e-05	0.000312	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Epirubicin—uterine cancer	1.57e-05	0.000311	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Doxorubicin—uterine cancer	1.57e-05	0.000311	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Doxorubicin—uterine cancer	1.57e-05	0.000311	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Doxorubicin—uterine cancer	1.56e-05	0.000308	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Doxorubicin—uterine cancer	1.55e-05	0.000307	CcSEcCtD
Medroxyprogesterone Acetate—Oedema peripheral—Doxorubicin—uterine cancer	1.55e-05	0.000306	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Etoposide—uterine cancer	1.54e-05	0.000305	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Doxorubicin—uterine cancer	1.54e-05	0.000305	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Epirubicin—uterine cancer	1.54e-05	0.000304	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Doxorubicin—uterine cancer	1.54e-05	0.000304	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Epirubicin—uterine cancer	1.53e-05	0.000303	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Epirubicin—uterine cancer	1.53e-05	0.000302	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Epirubicin—uterine cancer	1.52e-05	0.000301	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Etoposide—uterine cancer	1.52e-05	0.000301	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Doxorubicin—uterine cancer	1.51e-05	0.000299	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Epirubicin—uterine cancer	1.5e-05	0.000297	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Epirubicin—uterine cancer	1.49e-05	0.000294	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Doxorubicin—uterine cancer	1.48e-05	0.000294	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Epirubicin—uterine cancer	1.48e-05	0.000292	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Epirubicin—uterine cancer	1.48e-05	0.000292	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Etoposide—uterine cancer	1.47e-05	0.000291	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Doxorubicin—uterine cancer	1.47e-05	0.00029	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Doxorubicin—uterine cancer	1.46e-05	0.00029	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Doxorubicin—uterine cancer	1.46e-05	0.000288	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Epirubicin—uterine cancer	1.45e-05	0.000288	CcSEcCtD
Medroxyprogesterone Acetate—Tension—Epirubicin—uterine cancer	1.45e-05	0.000287	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Epirubicin—uterine cancer	1.45e-05	0.000286	CcSEcCtD
Medroxyprogesterone Acetate—Nervousness—Epirubicin—uterine cancer	1.43e-05	0.000284	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Epirubicin—uterine cancer	1.43e-05	0.000283	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Doxorubicin—uterine cancer	1.42e-05	0.000282	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Etoposide—uterine cancer	1.42e-05	0.000281	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Epirubicin—uterine cancer	1.42e-05	0.000281	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Doxorubicin—uterine cancer	1.42e-05	0.00028	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Doxorubicin—uterine cancer	1.41e-05	0.00028	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Doxorubicin—uterine cancer	1.41e-05	0.000279	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Doxorubicin—uterine cancer	1.39e-05	0.000274	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Doxorubicin—uterine cancer	1.37e-05	0.000272	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Epirubicin—uterine cancer	1.37e-05	0.000271	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Etoposide—uterine cancer	1.37e-05	0.00027	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Doxorubicin—uterine cancer	1.37e-05	0.00027	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Doxorubicin—uterine cancer	1.37e-05	0.00027	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Epirubicin—uterine cancer	1.36e-05	0.00027	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Epirubicin—uterine cancer	1.36e-05	0.000268	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Etoposide—uterine cancer	1.35e-05	0.000268	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Etoposide—uterine cancer	1.35e-05	0.000268	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Etoposide—uterine cancer	1.35e-05	0.000266	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Doxorubicin—uterine cancer	1.35e-05	0.000266	CcSEcCtD
Medroxyprogesterone Acetate—Tension—Doxorubicin—uterine cancer	1.34e-05	0.000265	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Doxorubicin—uterine cancer	1.34e-05	0.000265	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Epirubicin—uterine cancer	1.33e-05	0.000263	CcSEcCtD
Medroxyprogesterone Acetate—Nervousness—Doxorubicin—uterine cancer	1.33e-05	0.000263	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Epirubicin—uterine cancer	1.33e-05	0.000262	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Epirubicin—uterine cancer	1.32e-05	0.000262	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Doxorubicin—uterine cancer	1.32e-05	0.000261	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Doxorubicin—uterine cancer	1.31e-05	0.00026	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Epirubicin—uterine cancer	1.3e-05	0.000258	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Epirubicin—uterine cancer	1.3e-05	0.000257	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Epirubicin—uterine cancer	1.28e-05	0.000253	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Etoposide—uterine cancer	1.28e-05	0.000253	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Doxorubicin—uterine cancer	1.27e-05	0.000251	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Doxorubicin—uterine cancer	1.26e-05	0.00025	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Epirubicin—uterine cancer	1.26e-05	0.000249	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Epirubicin—uterine cancer	1.26e-05	0.000249	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Epirubicin—uterine cancer	1.26e-05	0.000249	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Doxorubicin—uterine cancer	1.26e-05	0.000248	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Epirubicin—uterine cancer	1.25e-05	0.000248	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	1.25e-05	0.000247	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Epirubicin—uterine cancer	1.24e-05	0.000246	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Doxorubicin—uterine cancer	1.23e-05	0.000244	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Epirubicin—uterine cancer	1.23e-05	0.000243	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Doxorubicin—uterine cancer	1.23e-05	0.000243	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Doxorubicin—uterine cancer	1.22e-05	0.000242	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Epirubicin—uterine cancer	1.21e-05	0.00024	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Doxorubicin—uterine cancer	1.21e-05	0.000239	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Epirubicin—uterine cancer	1.2e-05	0.000238	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Epirubicin—uterine cancer	1.2e-05	0.000238	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Doxorubicin—uterine cancer	1.2e-05	0.000238	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Epirubicin—uterine cancer	1.2e-05	0.000237	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Epirubicin—uterine cancer	1.19e-05	0.000235	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Doxorubicin—uterine cancer	1.18e-05	0.000234	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Epirubicin—uterine cancer	1.18e-05	0.000234	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Epirubicin—uterine cancer	1.18e-05	0.000233	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Epirubicin—uterine cancer	1.18e-05	0.000233	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Epirubicin—uterine cancer	1.17e-05	0.000232	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Epirubicin—uterine cancer	1.16e-05	0.000231	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Doxorubicin—uterine cancer	1.16e-05	0.00023	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Doxorubicin—uterine cancer	1.16e-05	0.00023	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Doxorubicin—uterine cancer	1.16e-05	0.00023	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Doxorubicin—uterine cancer	1.16e-05	0.000229	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	1.15e-05	0.000229	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Doxorubicin—uterine cancer	1.15e-05	0.000227	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Epirubicin—uterine cancer	1.15e-05	0.000227	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Doxorubicin—uterine cancer	1.14e-05	0.000225	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Epirubicin—uterine cancer	1.13e-05	0.000223	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Doxorubicin—uterine cancer	1.12e-05	0.000222	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Doxorubicin—uterine cancer	1.11e-05	0.000221	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Doxorubicin—uterine cancer	1.11e-05	0.000221	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Doxorubicin—uterine cancer	1.11e-05	0.000219	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Epirubicin—uterine cancer	1.1e-05	0.000217	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Doxorubicin—uterine cancer	1.1e-05	0.000217	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Doxorubicin—uterine cancer	1.09e-05	0.000216	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Doxorubicin—uterine cancer	1.09e-05	0.000216	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Epirubicin—uterine cancer	1.09e-05	0.000216	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Doxorubicin—uterine cancer	1.09e-05	0.000215	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Doxorubicin—uterine cancer	1.08e-05	0.000214	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Epirubicin—uterine cancer	1.08e-05	0.000214	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Doxorubicin—uterine cancer	1.08e-05	0.000213	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Epirubicin—uterine cancer	1.07e-05	0.000213	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Epirubicin—uterine cancer	1.07e-05	0.000212	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Doxorubicin—uterine cancer	1.06e-05	0.00021	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Epirubicin—uterine cancer	1.06e-05	0.00021	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	1.05e-05	0.000327	CbGpPWpGaD
Medroxyprogesterone Acetate—Decreased appetite—Epirubicin—uterine cancer	1.05e-05	0.000207	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Doxorubicin—uterine cancer	1.04e-05	0.000206	CcSEcCtD
Medroxyprogesterone Acetate—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	1.04e-05	0.000324	CbGpPWpGaD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Epirubicin—uterine cancer	1.04e-05	0.000206	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Epirubicin—uterine cancer	1.04e-05	0.000206	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Leptin signaling pathway—AKT1—uterine cancer	1.03e-05	0.000322	CbGpPWpGaD
Medroxyprogesterone Acetate—Constipation—Epirubicin—uterine cancer	1.03e-05	0.000204	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—PTEN—uterine cancer	1.03e-05	0.000319	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—KRAS—uterine cancer	1.02e-05	0.000318	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—PTEN—uterine cancer	1.02e-05	0.000317	CbGpPWpGaD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Doxorubicin—uterine cancer	1.02e-05	0.000201	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	1.01e-05	0.000314	CbGpPWpGaD
Medroxyprogesterone Acetate—Insomnia—Doxorubicin—uterine cancer	1.01e-05	0.0002	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—AKT1—uterine cancer	1e-05	0.000312	CbGpPWpGaD
Medroxyprogesterone Acetate—Paraesthesia—Doxorubicin—uterine cancer	1e-05	0.000198	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—INHBA—uterine cancer	9.98e-06	0.00031	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	9.97e-06	0.00031	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	9.97e-06	0.00031	CbGpPWpGaD
Medroxyprogesterone Acetate—Dyspnoea—Doxorubicin—uterine cancer	9.94e-06	0.000197	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Epirubicin—uterine cancer	9.93e-06	0.000196	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Doxorubicin—uterine cancer	9.91e-06	0.000196	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Epirubicin—uterine cancer	9.85e-06	0.000195	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Gene Expression—EZH2—uterine cancer	9.84e-06	0.000306	CbGpPWpGaD
Medroxyprogesterone Acetate—Dyspepsia—Doxorubicin—uterine cancer	9.81e-06	0.000194	CcSEcCtD
Medroxyprogesterone Acetate—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	9.8e-06	0.000305	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—EP300—uterine cancer	9.78e-06	0.000304	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of nuclear SMAD2/3 signaling—AKT1—uterine cancer	9.73e-06	0.000303	CbGpPWpGaD
Medroxyprogesterone Acetate—Decreased appetite—Doxorubicin—uterine cancer	9.69e-06	0.000192	CcSEcCtD
Medroxyprogesterone Acetate—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	9.66e-06	0.0003	CbGpPWpGaD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Doxorubicin—uterine cancer	9.62e-06	0.00019	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Doxorubicin—uterine cancer	9.61e-06	0.00019	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—uterine cancer	9.58e-06	0.000298	CbGpPWpGaD
Medroxyprogesterone Acetate—Urticaria—Epirubicin—uterine cancer	9.57e-06	0.000189	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	9.53e-06	0.000296	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	9.53e-06	0.000296	CbGpPWpGaD
Medroxyprogesterone Acetate—Constipation—Doxorubicin—uterine cancer	9.53e-06	0.000189	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Epirubicin—uterine cancer	9.52e-06	0.000188	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Epirubicin—uterine cancer	9.52e-06	0.000188	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—AKT1—uterine cancer	9.49e-06	0.000295	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—EP300—uterine cancer	9.39e-06	0.000292	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—VEGFA—uterine cancer	9.27e-06	0.000288	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	9.23e-06	0.000287	CbGpPWpGaD
Medroxyprogesterone Acetate—Feeling abnormal—Doxorubicin—uterine cancer	9.18e-06	0.000182	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Gene Expression—ESR2—uterine cancer	9.12e-06	0.000284	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	9.12e-06	0.000284	CbGpPWpGaD
Medroxyprogesterone Acetate—Gastrointestinal pain—Doxorubicin—uterine cancer	9.11e-06	0.00018	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—NRAS—uterine cancer	9.1e-06	0.000283	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—TP53—uterine cancer	9.09e-06	0.000283	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—CDKN2B—uterine cancer	9.05e-06	0.000282	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—AKR1C1—uterine cancer	8.98e-06	0.000279	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—CDKN2B—uterine cancer	8.92e-06	0.000277	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—VEGFA—uterine cancer	8.89e-06	0.000276	CbGpPWpGaD
Medroxyprogesterone Acetate—Hypersensitivity—Epirubicin—uterine cancer	8.88e-06	0.000176	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Doxorubicin—uterine cancer	8.85e-06	0.000175	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Doxorubicin—uterine cancer	8.81e-06	0.000174	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Doxorubicin—uterine cancer	8.81e-06	0.000174	CcSEcCtD
Medroxyprogesterone Acetate—AR—Generic Transcription Pathway—ESR1—uterine cancer	8.76e-06	0.000272	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CDKN2B—uterine cancer	8.74e-06	0.000272	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	8.72e-06	0.000271	CbGpPWpGaD
Medroxyprogesterone Acetate—Asthenia—Epirubicin—uterine cancer	8.64e-06	0.000171	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	8.6e-06	0.000267	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PGR—uterine cancer	8.54e-06	0.000266	CbGpPWpGaD
Medroxyprogesterone Acetate—Pruritus—Epirubicin—uterine cancer	8.52e-06	0.000169	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	8.5e-06	0.000264	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	8.47e-06	0.000263	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—SMAD3—uterine cancer	8.27e-06	0.000257	CbGpPWpGaD
Medroxyprogesterone Acetate—Diarrhoea—Epirubicin—uterine cancer	8.24e-06	0.000163	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Doxorubicin—uterine cancer	8.21e-06	0.000163	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—STK11—uterine cancer	8.17e-06	0.000254	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—CYP19A1—uterine cancer	8.17e-06	0.000254	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—YWHAE—uterine cancer	8.15e-06	0.000253	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—SMAD3—uterine cancer	8.14e-06	0.000253	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	8.11e-06	0.000252	CbGpPWpGaD
Medroxyprogesterone Acetate—Asthenia—Doxorubicin—uterine cancer	8e-06	0.000158	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Disease—SMAD3—uterine cancer	7.98e-06	0.000248	CbGpPWpGaD
Medroxyprogesterone Acetate—Dizziness—Epirubicin—uterine cancer	7.97e-06	0.000158	CcSEcCtD
Medroxyprogesterone Acetate—AR—Gene Expression—PGR—uterine cancer	7.9e-06	0.000246	CbGpPWpGaD
Medroxyprogesterone Acetate—Pruritus—Doxorubicin—uterine cancer	7.89e-06	0.000156	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—KRAS—uterine cancer	7.88e-06	0.000245	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—KRAS—uterine cancer	7.84e-06	0.000244	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—FBXW7—uterine cancer	7.81e-06	0.000243	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	7.78e-06	0.000242	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—AKR1B10—uterine cancer	7.73e-06	0.00024	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	7.68e-06	0.000239	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—AKT1—uterine cancer	7.67e-06	0.000239	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	7.67e-06	0.000238	CbGpPWpGaD
Medroxyprogesterone Acetate—Vomiting—Epirubicin—uterine cancer	7.66e-06	0.000152	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Doxorubicin—uterine cancer	7.63e-06	0.000151	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Disease—FGFR2—uterine cancer	7.61e-06	0.000237	CbGpPWpGaD
Medroxyprogesterone Acetate—Rash—Epirubicin—uterine cancer	7.6e-06	0.00015	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Epirubicin—uterine cancer	7.59e-06	0.00015	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Epirubicin—uterine cancer	7.55e-06	0.000149	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	7.53e-06	0.000234	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—EZH2—uterine cancer	7.5e-06	0.000233	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—CDKN2B—uterine cancer	7.43e-06	0.000231	CbGpPWpGaD
Medroxyprogesterone Acetate—Dizziness—Doxorubicin—uterine cancer	7.37e-06	0.000146	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Disease—MTHFR—uterine cancer	7.33e-06	0.000228	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—EP300—uterine cancer	7.31e-06	0.000227	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—SRD5A2—uterine cancer	7.22e-06	0.000224	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—NDUFB11—uterine cancer	7.22e-06	0.000224	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	7.21e-06	0.000224	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—PIK3CA—uterine cancer	7.2e-06	0.000224	CbGpPWpGaD
Medroxyprogesterone Acetate—Nausea—Epirubicin—uterine cancer	7.16e-06	0.000142	CcSEcCtD
Medroxyprogesterone Acetate—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	7.11e-06	0.000221	CbGpPWpGaD
Medroxyprogesterone Acetate—Vomiting—Doxorubicin—uterine cancer	7.09e-06	0.00014	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Doxorubicin—uterine cancer	7.03e-06	0.000139	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Doxorubicin—uterine cancer	7.02e-06	0.000139	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	7.01e-06	0.000218	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—TP53—uterine cancer	7e-06	0.000218	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	7e-06	0.000218	CbGpPWpGaD
Medroxyprogesterone Acetate—Headache—Doxorubicin—uterine cancer	6.98e-06	0.000138	CcSEcCtD
Medroxyprogesterone Acetate—AR—Gene Expression—ESR2—uterine cancer	6.95e-06	0.000216	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—AKR1C3—uterine cancer	6.91e-06	0.000215	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—PTEN—uterine cancer	6.91e-06	0.000215	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—STK11—uterine cancer	6.83e-06	0.000212	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—SMAD3—uterine cancer	6.78e-06	0.000211	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—HRAS—uterine cancer	6.66e-06	0.000207	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—ESR1—uterine cancer	6.64e-06	0.000207	CbGpPWpGaD
Medroxyprogesterone Acetate—Nausea—Doxorubicin—uterine cancer	6.62e-06	0.000131	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	6.62e-06	0.000206	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—EP300—uterine cancer	6.59e-06	0.000205	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	6.53e-06	0.000203	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—YWHAE—uterine cancer	6.43e-06	0.0002	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—RNF43—uterine cancer	6.4e-06	0.000199	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—SOCS3—uterine cancer	6.39e-06	0.000199	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	6.36e-06	0.000198	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—FBXW7—uterine cancer	6.16e-06	0.000192	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—MTHFR—uterine cancer	6.14e-06	0.000191	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CDKN2B—uterine cancer	6.12e-06	0.00019	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—PGR—uterine cancer	6.08e-06	0.000189	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	6e-06	0.000186	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—PGR—uterine cancer	5.99e-06	0.000186	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—IGF1R—uterine cancer	5.95e-06	0.000185	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—AKT1—uterine cancer	5.91e-06	0.000184	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—AKT1—uterine cancer	5.88e-06	0.000183	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—SRD5A2—uterine cancer	5.87e-06	0.000183	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NDUFB11—uterine cancer	5.87e-06	0.000183	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—INHBA—uterine cancer	5.85e-06	0.000182	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	5.8e-06	0.00018	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—EZH2—uterine cancer	5.78e-06	0.00018	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	5.7e-06	0.000177	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—EZH2—uterine cancer	5.69e-06	0.000177	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—CDKN2B—uterine cancer	5.66e-06	0.000176	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—SMAD3—uterine cancer	5.59e-06	0.000174	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—ESR1—uterine cancer	5.53e-06	0.000172	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.41e-06	0.000168	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—STK11—uterine cancer	5.39e-06	0.000168	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	5.39e-06	0.000168	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—ESR2—uterine cancer	5.36e-06	0.000167	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—FGFR2—uterine cancer	5.33e-06	0.000166	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—ESR2—uterine cancer	5.27e-06	0.000164	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—AKR1C1—uterine cancer	5.27e-06	0.000164	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—STAR—uterine cancer	5.22e-06	0.000162	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—AKR1B1—uterine cancer	5.22e-06	0.000162	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—SMAD3—uterine cancer	5.17e-06	0.000161	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	5.16e-06	0.00016	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—SOCS3—uterine cancer	5.04e-06	0.000157	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	4.9e-06	0.000152	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—PIK3CA—uterine cancer	4.88e-06	0.000152	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CDKN2B—uterine cancer	4.83e-06	0.00015	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—ERBB2—uterine cancer	4.78e-06	0.000149	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IGF1R—uterine cancer	4.69e-06	0.000146	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—ESR1—uterine cancer	4.56e-06	0.000142	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CDKN1B—uterine cancer	4.43e-06	0.000138	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—SMAD3—uterine cancer	4.41e-06	0.000137	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—CDKN2B—uterine cancer	4.36e-06	0.000136	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—CDKN2B—uterine cancer	4.29e-06	0.000134	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—AKR1B1—uterine cancer	4.25e-06	0.000132	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—STAR—uterine cancer	4.25e-06	0.000132	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—ESR1—uterine cancer	4.22e-06	0.000131	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—FGFR2—uterine cancer	4.21e-06	0.000131	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	4.2e-06	0.00013	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CTNNB1—uterine cancer	4.18e-06	0.00013	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—POLD1—uterine cancer	4.09e-06	0.000127	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—PTEN—uterine cancer	4.08e-06	0.000127	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—AKR1C3—uterine cancer	4.06e-06	0.000126	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CCL2—uterine cancer	4.02e-06	0.000125	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—AKT1—uterine cancer	3.98e-06	0.000124	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—SMAD3—uterine cancer	3.98e-06	0.000124	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PGR—uterine cancer	3.95e-06	0.000123	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—SMAD3—uterine cancer	3.92e-06	0.000122	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—EP300—uterine cancer	3.89e-06	0.000121	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NDUFB11—uterine cancer	3.87e-06	0.00012	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SRD5A2—uterine cancer	3.87e-06	0.00012	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—AKR1C1—uterine cancer	3.83e-06	0.000119	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—YWHAE—uterine cancer	3.77e-06	0.000117	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—NRAS—uterine cancer	3.64e-06	0.000113	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—FBXW7—uterine cancer	3.62e-06	0.000112	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—ESR1—uterine cancer	3.6e-06	0.000112	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PTEN—uterine cancer	3.41e-06	0.000106	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—RRM2—uterine cancer	3.41e-06	0.000106	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—ERBB2—uterine cancer	3.35e-06	0.000104	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—POLD1—uterine cancer	3.33e-06	0.000104	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—DCN—uterine cancer	3.31e-06	0.000103	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—EP300—uterine cancer	3.26e-06	0.000101	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—ESR1—uterine cancer	3.2e-06	9.95e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CXCL8—uterine cancer	3.17e-06	9.87e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CCL2—uterine cancer	3.17e-06	9.85e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—STK11—uterine cancer	3.16e-06	9.83e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—KRAS—uterine cancer	3.13e-06	9.74e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP11A1—uterine cancer	3.12e-06	9.71e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—AKR1C1—uterine cancer	3.12e-06	9.69e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CDKN1B—uterine cancer	3.1e-06	9.64e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—SOCS3—uterine cancer	2.96e-06	9.21e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—AKR1C3—uterine cancer	2.95e-06	9.17e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CTNNB1—uterine cancer	2.93e-06	9.11e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—PIK3CA—uterine cancer	2.88e-06	8.94e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PTEN—uterine cancer	2.85e-06	8.88e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CDKN2B—uterine cancer	2.83e-06	8.81e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—AKR1B1—uterine cancer	2.8e-06	8.71e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—STAR—uterine cancer	2.8e-06	8.71e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—RRM2—uterine cancer	2.78e-06	8.64e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IGF1R—uterine cancer	2.75e-06	8.56e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—EP300—uterine cancer	2.72e-06	8.47e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—DCN—uterine cancer	2.7e-06	8.38e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—HRAS—uterine cancer	2.66e-06	8.27e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—ERBB2—uterine cancer	2.64e-06	8.21e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—SMAD3—uterine cancer	2.59e-06	8.05e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—VEGFA—uterine cancer	2.58e-06	8.02e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—NRAS—uterine cancer	2.55e-06	7.92e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP11A1—uterine cancer	2.54e-06	7.9e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CXCL8—uterine cancer	2.5e-06	7.79e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—FGFR2—uterine cancer	2.47e-06	7.68e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CDKN1B—uterine cancer	2.45e-06	7.61e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PIK3CA—uterine cancer	2.41e-06	7.49e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—AKR1C3—uterine cancer	2.4e-06	7.46e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—AKT1—uterine cancer	2.35e-06	7.31e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CTNNB1—uterine cancer	2.31e-06	7.19e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—STK11—uterine cancer	2.3e-06	7.14e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP19A1—uterine cancer	2.3e-06	7.14e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PTEN—uterine cancer	2.25e-06	7e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—POLD1—uterine cancer	2.2e-06	6.83e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—KRAS—uterine cancer	2.19e-06	6.82e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.16e-06	6.7e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—EP300—uterine cancer	2.15e-06	6.68e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.06e-06	6.39e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—AKR1C1—uterine cancer	2.06e-06	6.39e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—VEGFA—uterine cancer	2.03e-06	6.33e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PIK3CA—uterine cancer	2.01e-06	6.26e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—NRAS—uterine cancer	2.01e-06	6.25e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—AKT1—uterine cancer	2e-06	6.21e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—AKT1—uterine cancer	1.97e-06	6.12e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TP53—uterine cancer	1.95e-06	6.06e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—STK11—uterine cancer	1.87e-06	5.81e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP19A1—uterine cancer	1.87e-06	5.81e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—HRAS—uterine cancer	1.86e-06	5.79e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CCL2—uterine cancer	1.86e-06	5.78e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—RRM2—uterine cancer	1.83e-06	5.7e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—DCN—uterine cancer	1.78e-06	5.53e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.75e-06	5.46e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—KRAS—uterine cancer	1.73e-06	5.38e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—MTHFR—uterine cancer	1.73e-06	5.37e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP11A1—uterine cancer	1.68e-06	5.21e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.67e-06	5.2e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—AKT1—uterine cancer	1.65e-06	5.12e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PIK3CA—uterine cancer	1.59e-06	4.94e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—AKR1C3—uterine cancer	1.58e-06	4.92e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ERBB2—uterine cancer	1.55e-06	4.82e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TP53—uterine cancer	1.54e-06	4.78e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—AKT1—uterine cancer	1.52e-06	4.73e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.52e-06	4.73e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CXCL8—uterine cancer	1.47e-06	4.57e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—HRAS—uterine cancer	1.47e-06	4.57e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CDKN1B—uterine cancer	1.44e-06	4.46e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—MTHFR—uterine cancer	1.4e-06	4.37e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CTNNB1—uterine cancer	1.36e-06	4.22e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PTEN—uterine cancer	1.32e-06	4.11e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—AKT1—uterine cancer	1.3e-06	4.04e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—EP300—uterine cancer	1.26e-06	3.92e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.24e-06	3.85e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—STK11—uterine cancer	1.23e-06	3.83e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP19A1—uterine cancer	1.23e-06	3.83e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—VEGFA—uterine cancer	1.19e-06	3.71e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NRAS—uterine cancer	1.18e-06	3.67e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—AKT1—uterine cancer	1.17e-06	3.64e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—AKT1—uterine cancer	1.15e-06	3.59e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KRAS—uterine cancer	1.01e-06	3.16e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PTEN—uterine cancer	9.6e-07	2.99e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PIK3CA—uterine cancer	9.32e-07	2.9e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—MTHFR—uterine cancer	9.26e-07	2.88e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—EP300—uterine cancer	9.15e-07	2.85e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TP53—uterine cancer	9.02e-07	2.81e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—HRAS—uterine cancer	8.63e-07	2.68e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PTEN—uterine cancer	7.81e-07	2.43e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—AKT1—uterine cancer	7.62e-07	2.37e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—EP300—uterine cancer	7.45e-07	2.32e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PIK3CA—uterine cancer	6.77e-07	2.11e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—AKT1—uterine cancer	5.53e-07	1.72e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PIK3CA—uterine cancer	5.51e-07	1.71e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PTEN—uterine cancer	5.15e-07	1.6e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—EP300—uterine cancer	4.91e-07	1.53e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—AKT1—uterine cancer	4.5e-07	1.4e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PIK3CA—uterine cancer	3.64e-07	1.13e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—AKT1—uterine cancer	2.97e-07	9.23e-06	CbGpPWpGaD
